Globus Medical (GMED) announced the completion of its previously disclosed acquisition of Nevro (NVRO). The acquisition of Nevro further expands Globus Medical’s presence in the musculoskeletal market, unlocking a $2.5B market opportunity. This strategic move positions Globus to further add to its product portfolio with the potential to alter the standard of care in the neuromodulation space and beyond. Globus Medical plans to discuss the closing of the acquisition and the anticipated benefits of the expanded product offering during its first quarter earnings conference in May.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Globus Medical price target lowered to $82 from $90 at Truist
- Buy Rating for Globus Medical’s ExcelsiusFlex: Surgeons’ Positive Feedback and FDA Approval Drive Optimism
- Globus Medical price target raised to $103 from $100 at Barclays
- Globus Medical’s Earnings Call: Record Revenue and Growth
- Globus Medical price target raised to $94 from $91 at BTIG